Learn More About VALEDA™
What Is Valeda PBM Light Therapy?
Valeda uses photobiomodulation (PBM) — three specific, science-backed wavelengths of low-level light — to stimulate energy production inside retinal cells. Dry AMD is linked to mitochondrial dysfunction in the retina; Valeda's light activates a key enzyme in retinal cells to boost cellular energy (ATP) production, supporting healthier retinal tissue and better visual function over time.
Who Is a Candidate for Valeda PBM?
Valeda is designed for patients with early to intermediate dry AMD, including those with:
● Medium or large drusen deposits
● Non-central geographic atrophy
● Best-corrected visual acuity between 20/32 and 20/70
It is not appropriate for patients with wet (neovascular) AMD or central-involving geographic atrophy, or for those with certain light sensitivities or seizure disorders. Our team will confirm candidacy with a comprehensive dilated eye exam.
What to Expect During Treatment
Valeda PBM is a quick, in-office treatment — no needles, no anesthesia, no dilation, and no downtime. A full treatment course is 54 sessions delivered over three courses per year across two years, with each course spaced three to five weeks apart.
Is Valeda PBM Effective?
In the LIGHTSITE III clinical trial, Valeda met its primary efficacy endpoint at Month 21. Among treated patients:
● 84% improved or maintained vision at about two years compared to baseline
● More than 60% gained one or more lines of vision improvement
● Zero reports of phototoxicity were recorded across three LIGHTSITE trials